BioNTech
BNTX
287 hedge funds and large institutions have $5.9B invested in BioNTech in 2022 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 105 increasing their positions, 80 reducing their positions, and 113 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 80
0.74% less ownership
Funds ownership: 15% → 14.26% (-0.74%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
19% less funds holding
Funds holding: 354 → 287 (-67)
35% less capital invested
Capital invested by funds: $9.07B → $5.9B (-$3.17B)
40% less call options, than puts
Call options by funds: $572M | Put options by funds: $946M
52% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 113
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Flossbach Von Storch
Cologne,
Germany
|
+$323M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$155M |
| 3 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$58M |
| 4 |
BlackRock
New York
|
+$55.6M |
| 5 |
D.E. Shaw & Co
New York
|
+$53.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$494M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$194M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$156M |
| 4 |
Coatue Management
New York
|
-$107M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$88.6M |
BNTX Hedge Fund Activity: Q1 2022 in Review
287 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q1 2022, worth a combined $5.9B — down 35% from $9.07B a quarter earlier.
Sellers outnumbered buyers: 113 funds closed out of BNTX and 54 opened new positions — a net loss of 59 holders — while 80 trimmed existing stakes and 105 added.
The largest buyer was Flossbach Von Storch, opening a new position worth an estimated $323M. The largest seller was Jennison Associates, cutting an estimated $494M.
- 287 institutional investors held BioNTech (BNTX) as of Q1 2022, down from 354 in Q4 2021.
- Funds reported $5.9B of BioNTech stock for Q1 2022, down 35% quarter-over-quarter.
- 54 funds opened new BioNTech positions in Q1 2022 and 113 closed out, a net change of -59 holders.
- The largest BioNTech buyer in Q1 2022 was Flossbach Von Storch, an estimated $323M added.
- The largest BioNTech seller in Q1 2022 was Jennison Associates, an estimated $494M sold.
Based on aggregated 13F filings for Q1 2022.